Advertisement

Pharmaceutical Research

, Volume 15, Issue 3, pp 461–465 | Cite as

Effect of Dose and Release Rate on Pulmonary Targeting of Liposomal Triamcinolone Acetonide Phosphate

  • Sandra Suarez
  • Ricardo J. Gonzalez-Rothi
  • Hans Schreier
  • Günther Hochhaus
Article

Abstract

Purpose. To demonstrate the importance of dose and drug release rate for pulmonary targeting of inhaled glucocorticoids using an animal model of intrapulmonary drug deposition.

Methods. Liposomes composed of 1,2-distearoyl phosphatidylcholine (DSPC), 1,2-distearoyl phosphatidylglycerol (DSPG) and triamcinolone acetonide phosphate (TAP) or liposomes containing triamcinolone acetonide (TA) were prepared by a mechanical dispersion method followed by extrusion through polycarbonate membranes. Encapsulation efficiency was assessed after size exclusion gel chromatography by reverse phase HPLC. The effect of liposome size (200 nm and 800 nm) on the release kinetics of water-soluble encapsulated material was determined in vitro at 37°C using 6-carboxyfluorescein as a marker and Triton X-100 (0.03%) as a leakage inducer. To investigate the relationship between drug release and pulmonary targeting, 100 μg/kg of TAP in 800 nm liposomes was delivered to male rats by intratracheal instillation (IT) and the results compared to data for 100 μg/kg TA liposomes (recently shown to exhibit a rapid drug release under sink conditions) and to previous studies reported for an equal dose of TAP in solution and TAP in 200 nm (1). Pulmonary targeting was assessed by simultaneously monitoring glucocorticoid receptor occupancy over time in lung and liver using an ex vivo receptor binding assay as a pharmacodynamic measure of glucocorticoid action. To assess the effect of dose on pulmonary targeting experiments were performed using 2.5, 7.5, 25, 100, and 450 μg/kg of TAP in 800 nm liposomes.

Results. The in vitro efflux of 6-carboxyfluorescein from (DSPC:DSPG) liposomes after exposure to Triton-X was biexponential. The terminal half-lives of 3.7 h and 9.0 h for the 200 nm and 800 nm liposomes, respectively, demonstrated that larger liposomes promote slower release of encapsulated water-soluble solute while previous results already indicated that encapsulation of lipophilic TA does not result in sustained release. Pulmonary targeting, defined as the difference between cumulative lung and liver receptor occupancies was most pronounced for the 800 nm liposomes (370%*h), followed by the 200 nm preparation (150%*h). No targeting was observed for TAP in solution (30%*h) or the rapid releasing TA liposome preparation. Correspondingly, the mean pulmonary effect time (MET) increased from 2.4−3.0 hr for TA liposomes or TAP in solution to 5.7 h and >6.2 h for TAP in 200 nm and in 800 nm liposomes, respectively. Escalating doses of TAP encapsulated in 800 nm liposomes revealed a distinct bell shaped relationship between the TAP dose and pulmonary targeting with a maximum occurring at 100 μg/kg (370%*h).

Conclusions. The in vivo data presented here confirm that pulmonary residence time and dose affect the extent of lung targeting of glucocorticoids delivered via the lung.

dose release rate pulmonary targeting liposomes glucocorticoid receptors sustained release triamcinolone acetonide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    R. Gonzalez-Rothi, S. Suarez, G. Hochhaus, H. Schreier, A. Lukyanov, H. Derendorf, and T. Dalla-Costa. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm. Res. 13:1699–1703 (1996).CrossRefPubMedGoogle Scholar
  2. 2.
    W. H. Nicolaizik, J. L. Marchant, M. A. Preece, and J. O. Warner. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 150:624–628 (1994).PubMedGoogle Scholar
  3. 3.
    M. Johnson. Pharmacodynamics and pharmacodynamics of inhaled glucocorticoids. J. Allergy Clin. Immunol. 97:169–176 (1996).PubMedGoogle Scholar
  4. 4.
    R. Brattsand and B. I. Axelsson. Basis of airway selectivity of inhaled glucocorticoids. In R. P. Schleimer, W. W. Busse, and P. M. O'Byrne (eds.), Inhaled glucocorticoids in asthma, Marcel Dekker, New York, US, 1997, pp. 351–379.Google Scholar
  5. 5.
    V. Vidgren, J. C. Waldrep, J. Arppe, M. Black, J. A Rodarte, W. Cole, and V. Knight. A study of 99mtechnetium-labelled beclo-methasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int. J. Pharm. 115:209–16 (1995).Google Scholar
  6. 6.
    G. Hochhaus, H. Mollmann, H. Derendorf, and R. Gonzalez-Rothi. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J. Clin. Pharmacol. 37:881–892 (1997).PubMedGoogle Scholar
  7. 7.
    G. Hochhaus, R. Gonzalez-Rothi, A. Lukyanov, H. Schreier, H. Derendorf, and T. Dalla-Costa. Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies. Pharm. Res. 12:134–137 (1995).PubMedGoogle Scholar
  8. 8.
    E. Ralston, L. M. Hjelmeland, R. D. Klausner, J. N. Weinstein, and R. Blumenthal. Carboxyfluorescein as a probe for liposome-cell interactions effect of impurities, and purification of the dye. Biochim. Biophys. Acta 649:133–137 (1981).Google Scholar
  9. 9.
    H. Schreier, A. N. Lukyanov, G. Hochhaus, and R. J. Gonzalez-Rothi. Thermodynamic and kinetic aspects of the interaction of triamcinolone acetonide with liposomes. Proceed. Inter. Symp. Control. Rel. Bioact. Mater. 21:228–229 (1994).Google Scholar
  10. 10.
    J. C. M. Stewart. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Chem. 104:10–14 (1980).Google Scholar
  11. 11.
    Y. Liu and L. Regen. Control over vesicle rupture and leakage by membrane packing and by the aggregation state of an attacking surfactant. J. Am. Chem. Soc. 115:708–713 (1992).Google Scholar
  12. 12.
    R. M. Fielding and R. M. Abra. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 9:220–223 (1992).PubMedGoogle Scholar
  13. 13.
    C. A. Hunt. Liposome Disposition in vivo: V. Liposome stability in plasma and implications for drug carrier function. Biochim. Biophys. Acta. 719, 450–463 (1982).PubMedGoogle Scholar
  14. 14.
    I. Gonda. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J. Pharm. Sci. 77:340–346 (1988).PubMedGoogle Scholar
  15. 15.
    G. Hochhaus and H. Derendorf. Dose optimization based on pharmacokinetic/pharmacodynamic modeling. In H. Derendorf and G. Hochhaus (eds.), Handbook of pharmacokinetic/pharmacodynamic correlation, CRC, New York, US, 1995, 79–120.Google Scholar
  16. 16.
    S. J. Farr, I. W. Kellaway, D. Parry-Jones, and S. G. Woolfrey. Proceed. Technetium as a marker of liposomal deposition and clearance in the human lung. Intern. Symp. Control. Rel. Bioact. Mater. 12:219–220 (1985).Google Scholar
  17. 17.
    J. Becker and R.-J. Grassa. Suppression of phagocytosis by dexamethasone in macrophage culture: Inability of arachidonic acid, indomethacin, and nordihydroaiaretic acid to reverse the inhibitory response mediated by a steroid-inducible factor. Int. J. Immunopharmac. 7:839–847 (1985).Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Sandra Suarez
    • 1
  • Ricardo J. Gonzalez-Rothi
    • 2
  • Hans Schreier
    • 3
  • Günther Hochhaus
    • 1
  1. 1.Department of Pharmaceutics, College of PharmacyUniversity of FloridaGainesville
  2. 2.Pulmonary DivisionUniversity of Florida and Gainesville VAMCGainesville
  3. 3.Advanced Therapies Inc.Novato

Personalised recommendations